Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | PHGDH | O43175 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16446620 | 0.80 | — | — | |
| SCHEMBL337229 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL720507 | 0.74 | — | — | |
| SCHEMBL4917540 | 0.73 | — | — | |
| SCHEMBL15483902 | 0.71 | KDM4E (0.31) | — | |
| SCHEMBL4917497 | 0.67 | — | — | |
| SCHEMBL1318771 | 0.67 | — | — | |
| SCHEMBL15483607 | 0.66 | — | — | |
| SCHEMBL4918245 | 0.64 | POLB (0.31) | — | |
| SCHEMBL983745 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027854-A1 | ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS | COILED THERAPEUTICS, INC. | 2023-01-26 | — | — | US | claimed |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-02-01 | — | — | US | claimed |
| WO-2021097352-A1 | ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS | A2A PHARMACEUTICALS, INC. (US) | 2021-05-20 | — | — | WO | claimed |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | THE INSTITUTE OF CANCER RESEARCH (GB) | 2019-09-17 | — | — | US | claimed |
| EP-3050885-B1 | BENZODIAZEPINE BROMODOMAIN INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2017-10-18 | — | — | EP | claimed |
| US-9718793-B2 | Isoxazole compounds as inhibitors of heat shock proteins | VERNALIS (R&D) LTD. (GB) | 2017-08-01 | — | — | US | claimed |
| US-9598420-B2 | Benzodiazepine bromodomain inhibitor | GLAXOSMITHKLINE LLC (US) | 2017-03-21 | — | — | US | claimed |
| US-20170049781-A1 | HSP90 INHIBITOR COMBINATIONS | NOVARTIS AG (CH) | 2017-02-23 | — | — | US | claimed |
| EP-2619197-B1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-08-05 | — | — | EP | claimed |
| US-20150209362-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | claimed |
| EP-1611112-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | Vernalis (Cambridge) Limited (GB) | 2006-01-04 | — | — | EP | claimed |
| WO-2004072051-A1 | ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-08-26 | — | — | WO | claimed |
| US-20040082786-A1 | Piperazine based inhibitors of factor xa | MILENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | claimed |
| US-20040072860-A1 | Piperazin-2-one amides as inhibitors of factor xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-15 | — | — | US | claimed |
| EP-1322643-A1 | PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR XA | Millennium Pharmaceuticals, Inc. (US) | 2003-07-02 | — | — | EP | claimed |
| EP-1322610-A2 | PIPERAZINE BASED INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2003-07-02 | — | — | EP | claimed |
| WO-2002026720-A2 | PIPERAZINE BASED INHIBITORS OF FACTOR Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| WO-2002026718-A2 | BICYCLIC PYRIMIDIN-4-ONE BASED INHIBITORS OF FACTOR XA | MILLENNIUM PHARMACEUTICAL, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| WO-2002026734-A1 | PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR Xa | COR THERAPEUTICS, INC. (US) | 2002-04-04 | — | — | WO | claimed |
| EP-0697443-B1 | Triphendioxazine reactive dyes | DYSTAR TEXTILFARBEN GMBH & CO (DE) | 2001-04-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027854-A1 | ISOXAZOLE DERIVATIVES TARGETING TACC3 AS ANTICANCER AGENTS | PTPRC, NFATC1, PTPRCAP | FDPS 3570/4885FAAH 4737/4885PHGDH 2521/4885 |
| US-20040082786-A1 | Piperazine based inhibitors of factor xa | TFPI, F11, F12 | FDPS 1641/4885FAAH 972/4885PHGDH 3743/4885 |
| US-20040072860-A1 | Piperazin-2-one amides as inhibitors of factor xa | F2, TFPI, TFPI2 | FDPS 2068/4885FAAH 849/4885PHGDH 4010/4885 |
| US-20150209362-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR | HSP90B1, HSP90AB1, HSP90AB2P | FDPS 3172/4885FAAH 3556/4885PHGDH 603/4885 |
| US-10413550-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | FDPS 4105/4885FAAH 3927/4885PHGDH 3938/4885 |
| US-11234987-B2 | Isoxazole compounds as inhibitors of heat shock proteins | HSP90AB1, HSP90AA1, HSP90AB2P | FDPS 4126/4885FAAH 3893/4885PHGDH 3972/4885 |
| US-20170049781-A1 | HSP90 INHIBITOR COMBINATIONS | HSP90AB1, HSP90B1, HSP90AA1 | FDPS 3107/4885FAAH 4448/4885PHGDH 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.